61 results about "Chronic renal insufficiency" patented technology

A compound having the structureuseful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, angina pectoris, thromboses, restenoses, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver in a human or animal patient.

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides core-shell compositions and pharmaceutical compositions thereof. Methods of use of the core-shell compositions for therapeutic and / or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of phosphate imbalance disorders, hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

A compound having the structureuseful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, angina pectoris, thromboses, restenoses, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver in a human or animal patient.

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides core-shell compositions and pharmaceutical compositions thereof. Methods of use of the core-shell compositions for therapeutic and / or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of phosphate imbalance disorders, hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

This inventions relates to compounds having the structure Formula Iand pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides core-shell compositions and pharmaceutical compositions thereof. Methods of use of the core-shell compositions for therapeutic and / or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of phosphate imbalance disorders, hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and / or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

The present invention is generally directed to compositions and formulations that can be used for the treatment of diseases such as End Stage Renal Disease (“ESRD”) and Chronic Renal Insufficiency (“CRI”). Specifically, it is directed to lanthanum-based compounds that bind phosphate and that can be formulated to provide for a reduced pill burden relative to other phosphate binders. In a formulation aspect of the present invention, a formulation is provided the includes a lanthanum-based, phosphate binder. The formulation is typically characterized in that in may be swallowed without chewing. Formulations of the present invention, along with a lanthanum-based compound, may optionally include the following: mass diluting agents; binders; coatings; compression / encapsulation aids; disintegrants; lubricants; plasticizers; slip / anti-electrostatic agents; powder lubricants; and, sweeteners. Where the formulation is in the form of a tablet, it typically has a volume between 0.3 cm3 and 1.2 cm3, preferably between 0.35 cm3 and 0.50 cm3. Each tablet typically includes enough phosphate binder such that only 3 or less tablets need to be ingested each day for a patient suffering from ESRD.

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides core-shell compositions and pharmaceutical compositions thereof. Methods of use of the core-shell compositions for therapeutic and / or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of phosphate imbalance disorders, hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

The invention discloses a compound alpha-keto acid dispersible tablet for treating chronic kidney diseases, containing four kinds of keto amino acid calcium, one kind of hydroxyamino acid calcium, five kinds of amino acid and pharmaceutically acceptable adjuvants. The tablet is mainly and clinically used for postponing renal failure process, correcting metabolic disturbance, coordinating with low-protein diet and preventing and treating damages caused by protein metabolism disorder because of chronic renal insufficiency.

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and / or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides core-shell compositions and pharmaceutical compositions thereof. Methods of use of the core-shell compositions for therapeutic and / or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of phosphate imbalance disorders, hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and / or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

There is disclosed a method of treating various diseases caused by micro-vasculature circulation problems, including, but not limited to, vascular insufficiency, phantom pain, diabetic neuropathy, neuropathic pain, autoimmune / inflammatory diseases (e.g., multiple sclerosis, Parkinson's disease, Crohn's Disease, lupus, rheumatoid arthritis, polymyalgia rheumatica, polymyositis, dermatomyositis, sarcoidosis), urinary retention, lymphoedema, and chronic renal insufficiency. Specifically, there is disclosed a treatment providing an effective amount of an acetyl cholinesterase inhibitor compound (or combination of compounds) to treat one or a plurality of microvasculature diseases.

The present invention discloses a Chinese medicine for effectively curing chronic nephrosis with obvious therapeutic effect. Said Chinese medicine is made up by using 12 Chinese medicinal materials of cooked rehmannia root, Chinese yam, moutan root bark, alisma tuber, poria, hedyotis and others through a certain preparation process. Said Chinese medicine has the functions of improving renal function, regulating lipometabolism, reducing urinary protein and raising immunity of body, so that it can be effectively used for curing the diseases of chronic renal insufficiency and renal failure, etc.

The invention discloses a traditional Chinese medicine composition for improving renal functions and restraining renal fibrosis. Active pharmaceutical ingredients of the traditional Chinese medicine composition comprise, by weight, 10-15 parts of the root of red-rooted salvia, 10-60 parts of astragalus membranaceus, 10-30 parts of herba epimedii, 5-30 parts of sinensis and 3-30 parts of prepared rhubarb. Clinical researches show that 168 patients with chronic renal insufficiency are treated by the traditional Chinese medicine composition, a remarkable clinical effect is obtained, clinical symptoms are reduced, the clinical symptoms of some patients are basically eliminated, the renal functions of the patients can be remarkably improved, blood urea nitrogen (BUN) and creatinine (Scr) are obviously reduced, and total effective rate achieves 88.66%. Animal researches show that the traditional Chinese medicine composition can delay development of chronic renal failure, and the mechanism of the traditional Chinese medicine composition is relative to effects of effectively restraining precipitation of renal tissue collagen and secretion of TGF (transforming growth factor)-beta, accordingly restraining renal fibrosis, and the like. The traditional Chinese medicine composition is low in clinical application cost and excellent in curative effect, and is safe and reliable.

The invention discloses a medicine for treating chronic renal insufficiency and chronic renal failure diseases. The medicine comprises the following raw materials in parts by weight: 70-90 parts of hairy antler, 17-23 parts of prepared common monkshood daughter root, 70-90 parts of cassia twig and 170-230 parts of all-grass of desertliving cistanche; preferably, the medicine also comprises the following raw materials in parts by weight: 170-230 parts of common macrocarpium fruit, 85-115 parts of prepared rhizome of rehmannia, 170-230 parts of largehead atractylodes rhizome, 170-230 parts of Chinese angelica and 45-55 parts of astragalus membranaceus; preferably, the medicine also comprises the following raw materials in parts by weight: 170-230 parts of Indian buead, 170-230 parts of plantain seed and 17-23 parts of root-bark of tree peony; and preferably, the medicine also comprises the following raw materials in parts by weight: 85-115 parts of twotooth achyranthes root and 45-55 parts of rheum rhabarbarum. The medicine disclosed by the invention can be used for tonifying the kidney-qi, strengthening the kidney-yang and recovering the renal functions, and can be used for treating chronic renal insufficiency, chronic renal failure, limb weakness, waist-knee-limb coldness, difficult urination, frequent urination or nighttime micturition, bleak or dark complexion, sluggish in facial expression, double-limb pitting edema, face and eye edema, urea nitrogen increase, creatinine increase, hypertensive nephropathy and diabetic nephropathy caused by insufficiency of kidney-yang, and treating the chronic renal insufficiency and chronic renal failure diseases caused by medicine injury or other reasons.

(S)-(−)-5-hydroxy-1-methylhydantoin is useful as a drug having high safety. Since the compound of the present invention, (S)-(−)-5-hydroxy-1-methylhydantoin, rarely changes to the metabolite having high toxicity compared with the R-form and the racemate, it is preferred as an agent for renal failure especially when used for chronic renal insufficiency in a patient where toxic substances are not excreted, but are accumulated in the body due to disturbance of renal functions.

The invention discloses a type of polyethylene glycol erythropoietin, which is prepared from non-glycosylated rhEPO(rhngEPO) or point mutant thereof, and N-terminal amino of single and single chain PEG molecule having molecular weight greater than 20kDa or mercapto of cysteine mutational state by fixed point coupling, wherein the olyethylene glycol erythropoietin has the molecular structural formula of CH3-(CH2CH2-O)n-(CH2)r-NH-rhngEPO or CH3-(CH2CH2-O)n-X-S-rhngEPOm, wherein n is 100 to 2,200, r is 0 to 4, and X is S or C. The PEG-rhngEPO or PEG-rhEPOm molecule simultaneously has long-acting preparation characteristics such as long acting, high efficiency and low immunogenicity, and establishes foundation for preparing parent long-acting preparation for treating anemia caused by chronic renal insufficiency, tumor, anemia caused by AIDS chemotherapy, marrow brain nerve damage, and selective operation auto-transfusion.

The invention discloses a Chinese medicinal formulation for treating chronic renal insufficiency, which is prepared from Chinese medicinal herbs including American ginseng, hairy deerhorn, white atractylodes rhizome, Poria cocos, amomum fruit, Cinnamomum cassia, lepidium seed, talcum powder, Ligusticum wallichii, cuttlebone through rouging, frying, washing, mixing and disintegrating, sieving, split charging, and disinfecting.

The invention relates to use of cordyceps cicadae in preparation of drugs for preventing or treating gout. According to the use, due to cordyceps cicada preparation products, a novel gout preventing or treating method is provided and is obvious in effect. The cordyceps cicadae have the functions of reducing blood and urine creatinine, increasing endogenous creatinine clearance rate, increasing the content of serum protein, reducing the discharge of urinary protein, and the like. Therefore, the cordyceps cicadae have definite treatment effect on early- and middle-stage chronic renal insufficiency patients. Confirmed by further researches: the cordyceps cicadae have relatively good treatment effect on renal tubulointerstitial lesions and can be used for protecting Na<+>-K<+>-ATPase of renal tubule cells, alleviating cytolysosome and cell lipid peroxidation injury, improving renal hemodynamics and alleviating endothelial cell injury and blood coagulation property.

The invention belongs to the technical field of traditional Chinese medicine preparations and relates to traditional Chinese medicine pills for treating chronic renal insufficiency. The traditional Chinese medicine pills are characterized by being prepared from 17 traditional Chinese medicinal materials including Fructus Corni, Rhizoma Dioscoreae, Radix Rehmanniae, Radix Astragali and the like according to certain weight percentages. By combination of the three nourishing materials including Fructus Corni, Rhizoma Dioscoreae, Radix Rehmanniae and the spleen invigorating and Qi replenishing materials including Radix Astragali, Rhizoma Atractylodis Macrocephalae, Radix Codonopsis and Rhizoma Pinellinae Praeparata, efficacies of spleen and kidney tonifying, Qi replenishing and detoxifying are achieved. Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae and Rhizoma Ligustici Wallichii have efficacies of blood replenishing and blood circulation promoting. By compatibility of three purgative materials including Poria Cocos, Rhizoma Alismatis and Cortex Moutan to Rheum Officinale, Cortex Mori, Radix Salviae Miltiorrhizae and Radix Polygonum Multiflorum Preparata, efficacies of heat purging, blood circulation promoting and stasis removing are achieved. Kidney tonifying and protecting can be realized while diuresis promoting and detoxifying are realized to reduce kidney damages, and efficacies of kidney blood circulation improving and Qi and blood circulation promoting are achieved. Treatment of both symptoms and root causes is realized, and the traditional Chinese medicine pills are excellent in clinical treatment effect, stable in curative effect, free of toxic and side effects and low in cost and shorten kidney function recovery period. The problems of lack of purposefully applicable medicines and barely satisfactory treatment effects due to large differences of clinical cases are solved.

The present invention discloses a Chinese medicine for curing chronic nephritis and chronic renal insufficiency with obvious therapeutic effect and small size effect. Said invention is made up by using 7 Chinese medicinal materials of centella, cornus fruit, ligusticum root, astragalus root, salvia root and others.

The invention discloses a traditional Chinese medicinal formula for treating diabetes with chronic renal insufficiency, and relates to the technical field of traditional Chinese medicines for treating the diabetes. The formula is characterized in that the above composition comprises, by weight, 20-40 parts of Rhizoma Alismatis, 20-40 parts of Atractylodes lancea, 5-15 parts of rhizoma gastrodiae, 5-15 parts of Gambir Plant, 55-65 parts of Radix Astragali, 10-30 parts of Salvia miltiorrhiza, 10-30 pars of Radix Puerariae, 10-30 parts of sweet potato flesh, 5-15 parts of Ligusticum wallichii, 5-15 parts of Radix aconiti lateralis preparata, 10-30 parts of Radix Ophiopogonis, 3-8 parts of Divaricate Saposhnikovia Root, 5-15 parts of Chinese angelica, 20-40 parts of Lycium Chinense and 5-15 parts of prepared rehmannia root. The composition can control the blood sugar, can stabilize and treat the diabetes with chronic renal insufficiency, has no side effects on human bodies, and has good medicinal properties.

The invention relates to medical preparation containing levocarnitine and dihydroxybenzenesulphonic acid salt and a preparation method of the medical preparation, and particularly relates to an orally taken solid medical preparation. The medical preparation contains the levocarnitine, the dihydroxybenzenesulphonic acid salt and pharmacologically receivable excipient, and the levocarnitine and the dihydroxybenzenesulphonic acid salt are separately granulated in a preparation process of the preparation. The invention further relates to the preparation method for the orally taken solid medical preparation and application for treating and / or preventing diseases affecting renal functions, such as primary nephritis, secondary nephritis, renal ischemia / reperfusion injury, renal insufficiency (for example, chronic renal insufficiency), nephrotic syndrome, renal failure (for example, chronic renal failure), uremia and diabetic nephropathy, and complications caused by the diseases affecting the renal functions, such as cardiovascular disease (for example, myocardial ischemia / reperfusion and chronic cardiac insufficiency) and diabetes mellitus.

The invention relates to a traditional Chinese medicine composition for treating chronic renal insufficiency, and relates to the technical field of traditional Chinese herbal medicine. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 25 to 35 parts of rhizoma alismatis, 25 to 35 parts of rhizoma atractylodis, 5 to 15 parts of gastrodia elata, 5 to 15 parts of uncaria rhynchophylla, 55 to 65 parts of astragali radix, 15 to 25 parts of salvia miltiorrhiza, 15 to 25 parts of radix puerariae, 15 to 25 parts of dogwood, 5 to 15 parts of ligusticum wallichii, 5 to 15 parts of radix aconiti lateralis preparata, 15 to 25 parts of radix ophiopogonis, 5 to 10 parts of Chinese parsnip root, 5 to 15 parts of angelica sinensis, 25 to 35 parts of medlar and 5 to 15 parts of prepared rhizome of rehmannia. The traditional Chinese medicine composition has the functions of nourishing the spleen and kidney, improving the blood, clearing away the heat and relieving internal heat of fever and is used for treating the diseases such as chronic renal insufficiency, renal failure and uremia. The traditional Chinese medicine composition for treating the chronic renal insufficiency has the characteristics that the raw materials are easy to get, simplicity in preparation is realized, the cost is low, the practicability is good, and the like.

The invention relates to a medical instrument for nephrology department. The medical instrument comprises a tube body, a guide supporting rod and a supporting frame tube, wherein the guide supporting rod is fixedly arranged at an upper end of the tube body, the guide supporting rod is movably arranged in the supporting frame tube, a limiting assembly is arranged outside the tube body, and the limiting assembly is used for limiting and guiding the tube body. By improving existing equipment for treating chronic renal insufficiency, the improved equipment for treating chronic renal insufficiency can realize an adjustable performance of a heating contact, so that in an actual use process, the adjustable performance of the heating contact can be realized, medicaments can be added to different parts of the intestinal tract, and a traditional Chinese medicine decoction at different parts can be heated through the medical instrument, so that the traditional Chinese medicine decoction can be better absorbed.

A Chinese medicine in the form of dripping pill for treating cough, asthma, weakness, insomnia, hypomnesia, menoxenia, impotence, ejaculation praecox, chronical bronchitis, chronic renal insufficiency, hyperlipemia, hepatocirrhosis, etc is prepared from cordyceps and medicinal carrier.